CONGRESS AND EVENTS
In 2003 we launched our popular biennial congress, which now attracts up to 2,700 participants from around 90 countries across the world.
Our focus is on promoting scientific excellence, facilitating diversity and participation in science and channelling outstanding science to have maximum impact on the ground. This involves developing relationships across all disciplines relating to microbiology and across all sectors – academic, policy, business, educational, communications and recreational – and helping to put the right people “in the same room”.
We do this through our business development work, and building and strengthening our network of members, editors, and grantees, but with face-to-face interaction still critical to build the right collaborations. Our Congress and FEMS-sponsored meetings are a key element of our network-building activities.
Our vision is to:
- preserve scientific excellence and trust
- diversify, improve and extend networking opportunities
- provide a platform for established researchers, students and other parties to discuss and exchange knowledge
- improve links with professional development
- improve the offer for sponsors and exhibitors
- combine the transdisciplinary advantages of a large congress with the disciplinary detail and networking atmosphere of a small specialist conference
- improve opportunities and benefits for our Member Societies
The next FEMS Congress
The 8th Congress of European Microbiologists (FEMS 2019) is one of the leading meetings of its kind and will connect thousands of microbiologists from around the world.
FEMS 2019 will be held 7-11 July in Glasgow, UK.
Sponsoring and exhibition
The FEMS 2019 Congress Support & Exhibition Prospectus is available via this link.
The aim of this study was to determine whether in vitro induced erythromycin resistance facilitates the cross-resistance to the novel fluoroketolide, solithromycin, in Staphylococcus aureus. Long-term exposure of erythromycin results in resistance to ketolides in S. aureus through drug binding site mutations. These results demonstrate that since erythromycin has been used clinically for a long time, it is necessary to carefully evaluate the rewards and risks when prescribing solithromycin for the treatment of infectious diseases.